Last updated: 2026-10-08 23:02:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
InspireMD, Inc. (NSPR) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $0.48, with a market capitalization of $24.60M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.47 to $2.54. This page covers its latest market performance, valuation, price trends and company information.
$24.60M | |
$0.50 | |
$24,937,500.00 | |
$0.47 | |
$0.51 | |
225.24K | |
77.10K | |
-- | |
$2.54 | |
$0.47 | |
-- | |
-- |
InspireMD, Inc. (NSPR) is trading at $0.48 in after-hours trading as of 2026-10-08 22:39:00, down 7.59% ($0.04) from the regular-session close of $0.51.
After-hours trading shows how investors are pricing NSPR after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, InspireMD, Inc. (NSPR) moved from $0.69 to $0.48, representing a decline of 31.10% ($0.22).
The stock traded between $0.47 and $0.71 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 142.27 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
NSPR is currently trading at $0.48, placing it 0.4% of the way from its 52-week low of $0.47 to its 52-week high of $2.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 127 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of InspireMD, Inc. (NSPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.